If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
200
results.
Updated on
14/09/2026 [06:52:00]
Results 100 to 125 of 200
Absstract of: CN122685538A
本发明公开了一种含有氨基甲酸酯的阳离子脂质、包含其的组合物及用途，具体公开了一种式(I)所示的阳离子脂质。本发明提供的阳离子脂质能特异性地递送药物到特定的细胞，同时可显著降低细胞毒性，有助于发挥药物的疗效，能够提升药物在体内的靶向递送效率和安全性。
Absstract of: CN122681817A
本发明公开了一种纳米材料Q‑MNPS及其制备方法和在脑缺血神经保护中的制药新用途，涉及生物医药技术领域。包括：金属‑药物配位聚合物内核；包覆所述内核的天然细胞膜外壳；其中，所述金属‑药物配位聚合物内核在活性氧环境下发生解离，释放药物分子；所述天然细胞膜外壳赋予所述纳米颗粒穿透血脑屏障的能力。本发明通过天然细胞膜外壳的生物伪装特性实现血脑屏障穿透，利用金属‑药物配位聚合物内核的活性氧响应性在缺血病灶定点释放药物，具有优异的神经保护作用，能够显著改善神经功能缺损并降低死亡率。
Absstract of: CN122681823A
本发明公开了一种透明质酸、L‑精氨酸包覆复合纳米粒子及其制备方法，涉及医药技术领域；该复合纳米粒子以β‑环糊精包载伏立诺他（SAHA）形成纳米粒子，外层包覆氧化透明质酸（OHA）和L‑精氨酸（L‑Arg）；制备过程中，先通过透析法制得纳米粒子，再依次加入OHA和L‑Arg进行避光反应，最终得到CS@OL复合纳米粒子；该粒子平均粒径为87nm，在室温下21天内保持稳定。本发明复合纳米粒子具有良好的自由基清除能力、细胞相容性、跨内皮递送能力及靶向炎症细胞的能力，能够协同递送SAHA和L‑Arg，调节ROS/NO稳态，抑制炎症反应，适用于动脉粥样硬化等氧化应激相关疾病的治疗。
Absstract of: CN122681819A
本发明公开一种负载二烯丙基三硫化物的长双歧杆菌来源细胞外囊泡纳米复合物，包括：长双歧杆菌来源细胞外囊泡（BL‑EVs），以及负载于BL‑EVs中的二烯丙基三硫化物（DATS）；纳米复合物是通过将BL‑EVs与DATS混合后进行共挤出及孵育处理制得的、具有单分散囊泡结构的纳米复合物实体。本发明的纳米复合物具备细胞内微环境刺激响应性，在被牙周相关细胞摄取进入胞内后，特异性响应于胞内谷胱甘肽微环境触发内部有机硫键断裂，并在胞内靶向缓释硫化氢，用以通过上调靶细胞抗氧化保护蛋白的表达与活性以产生抗氧化增效作用，并在此基础上，协同诱导巨噬细胞向抗炎修复型M2巨噬细胞重塑，同时上调牙龈成纤维细胞抗铁死亡保护蛋白的表达与活性以阻断其铁死亡进程。
Absstract of: CN122686807A
本发明涉及生物医药技术领域，具体涉及用于特异性检测tRNA来源小片段RNA 5‑GlyTCC‑L33表达水平的试剂在制备用于胎儿生长受限辅助评估产品中的应用，5‑GlyTCC‑L33模拟物在制备用于胎儿生长受限实验动物模型构建的模型诱导试剂或模型诱导组合物中的应用，以及相关试剂盒；本发明通过对正常妊娠与胎儿生长受限胎盘组织进行小RNA测序分析，发现5‑GlyTCC‑L33在胎儿生长受限胎盘组织中显著上调，通过检测离体胎盘绒毛膜组织样本中5‑GlyTCC‑L33的表达水平，并与正常妊娠对照水平或预设参考阈值比较，可生成体外检测结果或辅助判读信息可作为胎儿生长受限辅助评估的候选分子标志物。
Absstract of: CN122681898A
本发明公开了C‑C基序趋化因子受体作为治疗子宫瘢痕新靶点的应用。CCR1作为子宫瘢痕疾病的全新治疗靶点，能够推动子宫瘢痕病变持续进展，通过磷酸化下游Six1、促进细胞外基质生成，进而介导子宫瘢痕产生。通过沉默该受体，可有效阻滞子宫瘢痕的发生与发展，提升女性妊娠成功率，并减少各类不良妊娠结局的出现。本方案的制备工艺为：将可电离脂质、DSPC、胆固醇、DMG‑PEG混合溶解在乙醇中，将siCCR1置于柠檬酸缓冲液中，乙醇相和水相通过微流体装置混合，在PBS溶液中透析两小时后制备成脂质纳米粒。该脂质纳米粒与聚卡波非、泊洛沙姆复配，制备得到复合水凝胶。该水凝胶可于子宫病灶局部释放siCCR1，有效抑制组织纤维化、减少胶原沉积，进而实现子宫瘢痕修复。其具备优异的生物相容性，给药方式无创，可实现药物长效缓释，减少给药频次。
Absstract of: CN122682090A
本发明公开了一种用于椎间盘退变修复的聚多巴胺修饰ZnO/BaTiO3异质结复合材料及其制备方法，属于生物医用材料技术领域。该材料以四方相钛酸钡为核心、表面原位生长氧化锌构建II型异质结，并包覆聚多巴胺功能层。制备时，先水热法制备钛酸钡，再经溶剂蒸发与高温煅烧引入氧化锌，最后在多巴胺溶液中自聚包覆。本发明利用超声驱动异质结产生声电耦合效应，II型异质结促进载流子分离以提升压电催化活性，PDA涂层清除活性氧、缓解炎症。体外实验证实该材料促进髓核细胞基质合成、抑制炎症，动物实验验证其延缓椎间盘退变。本发明通过“声电转化‑电荷分离‑电刺激‑环境重塑”一体化设计，为深部组织修复提供了高效无创策略。
Absstract of: CN122685654A
本发明属于生物医药的技术领域，公开了一种核酸药物选择性递送的膦酯化可电离脂质及其制备方法与应用。所述膦酯化可电离脂质其结构通式为式I，式I中Cn为含有膦酯的结构，Nn为含氮的环状结构或含氮的胺基基团，B为O或NH；Ln作为连接键。本发明还公开了膦酯化可电离脂质的制备方法。本发明的膦酯化可电离脂质用于制备膦酯化可电离脂质纳米颗粒，作为核酸药物选择性递送至心、肺脏、脾脏、肝脏和/或肌肉递送载体。本发明的可电离脂质协同整合了膜稳定性与内涵体逃逸功能，有效规避传统靶向修饰中存在的蛋白冠屏蔽效应，能够将核酸药物高效、安全地递送至肝外器官，特别是肺和脾。式I：。
Absstract of: CN122681818A
本发明属于生物医药技术领域，具体涉及一种靶向多发性骨髓瘤细胞的细胞膜材料及其制备方法和应用。本发明要解决的技术问题是骨髓瘤细胞治疗药物缺乏足够的跨骨髓屏障递送和肿瘤靶向性，且易造成全身性毒副作用。本发明解决技术问题的技术方案是提供了一种靶向多发性骨髓瘤细胞的细胞膜材料。该膜材料为表面表达有抗GPRC5D的抗体的细胞的细胞膜。本发明细胞膜材料继承有膜源细胞“骨髓归巢”效应增强药物的跨骨髓屏障递送，并对多发性骨髓瘤细胞表面GPRC5D配体有主动靶向结合能力，可实现高效递送药物至骨髓腔内的肿瘤部位并高效摄取入多发性骨髓瘤细胞，进而实现药物在骨髓病灶处的精准富集与释放，从而提高治疗效果，降低全身毒性，为多发性骨髓瘤的治疗提供了一种有效的药物载体方案。
Absstract of: CN122685532A
本文提供一种脂质化合物，其可与其他脂质成分(例如中性脂质、胆固醇和聚合物结合脂质)组合使用，以形成脂质纳米颗粒，用于递送治疗剂(例如核酸分子)以用于治疗或预防目的。本文还提供包含式I所示脂质化合物的脂质纳米颗粒组合物。
Absstract of: CN122681816A
本发明公开了一种中性粒细胞介导的工程化交叉纳米囊泡递送平台及其应用，属于生物医药技术领域，该递送平台由外源性胆固醇富集的LNV‑SyBV杂合囊泡及其负载的多粘菌素B组成；外源性胆固醇富集的LNV‑SyBV杂合囊泡由植物来源抗炎囊泡、减毒细菌囊泡、外源性胆固醇制备；植物来源抗炎囊泡为柠檬来源的纳米囊泡LNV；减毒细菌囊泡为大肠杆菌来源的合成囊泡SyBV。本发明一种中性粒细胞介导的工程化交叉纳米囊泡递送平台及其应用，通过靶向递送、抗菌抗炎双重功能及低免疫毒性，为碳青霉烯耐药革兰氏阴性菌感染的临床治疗提供了创新策略。
Absstract of: CN122681824A
本发明涉及生物材料技术领域，公开了一种基于花瓣形MnO2纳米复合材料、制备方法及应用，步骤1：高锰酸钾溶液中加入油酸钠，充分反应，得到MnO2；步骤2：MnO2溶液中加入氯铂酸，充分搅拌后，加入抗坏血酸进行还原反应，经热处理即可得到Pt‑SAC；步骤3：Pt‑SAC分散于氯化钙溶液中，调节pH至碱性，充分反应得到Pt‑SAC@ CaO2；步骤4：将活化后的叶酸滴加入壳聚糖溶液中，充分反应后透析，加入Pt‑SAC@ CaO2，充分反应后即可得到所需纳米复合材料；本发明通过在MnO2纳米花载体上制造氧空位，成功锚定Pt单原子，并进一步负载CaO2与CS‑FA靶向外壳，构建靶向、自供应H2O2和外源性Ca2+的化学动力学治疗‑钙死亡协同纳米平台。
Absstract of: CN122681822A
本发明涉及生物医药技术领域，且公开了一种巨噬细胞膜仿生纳米粒靶向SPP1抗肾纤维化药物系统，该系统包含PLGA纳米粒内核、能够结合并中和SPP1蛋白活性的抗体以及具有炎症趋化和病灶归巢能力的巨噬细胞膜包裹层，抗体负载于PLGA纳米粒内核表面，巨噬细胞膜包裹层包覆于负载抗体的PLGA纳米粒外表面形成核‑壳结构。制备方法包括滴加法制备PLGA纳米粒、抗体负载、低渗裂解提取巨噬细胞膜、超声和挤出完成膜包裹。该系统利用巨噬细胞膜天然携带的炎症趋化受体实现肾纤维化病灶主动靶向归巢，在肾纤维化模型中能够降低纤维化面积，促进E‑cadherin恢复，延长体内循环时间，提高病灶富集浓度。
Absstract of: CN122681821A
本发明公开了一种用于肺部高效递送厚朴酚的类脂质纳米递药系统及其制备方法与应用，由脂质材料4A3‑SC8、1,2‑二油酰基‑3‑三甲基铵‑丙烷、胆固醇、1,2‑二肉豆蔻酰‑rac‑甘油‑3‑甲氧基聚乙二醇2000、1,2‑二油酰基‑sn‑甘油‑3‑磷酸乙醇胺与厚朴酚自组装而成。其优点在于，利用阳离子‑π及疏水作用实现了不带电中药厚朴酚的高效包载，克服了其易结晶、易泄漏的难题；利用内源性电荷屏蔽效应实现高浓度阳离子脂质投入下的低表面电荷，降低了毒性风险。该递药系统经气道局部给药后可在肺部原位构筑抗病毒屏障，并协同抑制冠状病毒NSP12/NSP14复制酶活性，在动物模型中表现出超越一线临床用药的体内保护效果。本发明为中药小分子的肺高效递送及呼吸道抗病毒治疗提供了新的制剂平台。
Absstract of: WO2025048497A1
The present invention relates to a novel histidine amide cholesterol compound and RNA delivery lipid nanoparticles comprising same. The present invention can have improved mRNA delivery efficiency and expression efficiency while having biocompatibility.
Absstract of: WO2025049925A2
The present disclosure provides compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications.
Absstract of: US20260258411A1
0000 The present disclosure is directed to self-cleaving ribozyme constructs designed to target specific organisms and introduce exogenous sequences—both coding and non-coding-into expressed RNAs of the target host cell.
Absstract of: US20260258503A1
According to one embodiment of the present disclosure, a method for fusing lipid nanoparticles is provided. In some embodiments, the method is a method including: causing a fibrous structure to capture a first lipid nanoparticle; causing the fibrous structure to capture a second lipid nanoparticle; and causing the fibrous structure to contract.
Absstract of: WO2026179199A1
The present invention discloses a block copolymer nanoparticle having liquid crystal properties, a method for preparing same, and use thereof. The structural formula of the block copolymer nanoparticle is represented by formula (1). In the present invention, by using the characteristic kinetic traps in the polymerization-induced self-assembly method, liquid crystal block copolymer nanoparticles with a high solid content and a uniform size are obtained. The present invention can not only obtain traditional worm-like liquid crystal block copolymer micelles, but also obtain spherical liquid crystal block copolymer micelles with an adjustable degree of birefringence. The present invention not only improves the processability of the liquid crystal block copolymer nanoparticles, but also significantly improves the possibility of large-scale manufacturing thereof by increasing the solid content, possessing remarkable application prospects in polymer materials and biopharmaceutics.
Absstract of: US20260256696A1
0000 The present invention provides lipid nanoparticles containing
(A) an ionic lipid represented by the formula (1):
0000
0000 (the symbols in the formula (1) are as defined in the DESCRIPTION),
(B) vitamin E and/or a derivative thereof,
(C) phospholipid,
(D) cholesterol, and
(E) PEG lipid.
Absstract of: US20260256963A1
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.
Absstract of: US20260256705A1
0000 Provided is a lipid formulation capable of forming a lipid-based nanoparticle comprising an ionizable lipid to phospholipid molar ratio of 0.1-1.30 of in association with a nucleic acid payload, and in some embodiments, a stabilizing agent. In embodiments, the nucleic acid payload is a vaccine genetic element.
Absstract of: WO2026183142A2
The present disclosure provides compositions, methods of making, and use of a circular ribonucleic acid (circRNA) therapeutic for targeted delivery to immune cells, including T cells, for effector functions such as B cell depletion, providing, among other things, methods of treating B cell-mediated diseases such as autoimmune disease and cancer, meeting the medical need for efficacious and safe therapies that overcome the disadvantages of ex vivo CAR T therapy. Provided by the present disclosure is a circRNA therapeutic comprising: (i) a circRNA comprising a ribosome recruiting element, and a coding sequence encoding a CAR comprising, for example, an anti-CD19 antibody or antigen-binding fragment thereof, and (ii) a targeting moiety (e.g, anti-CD5) that binds to an immune cell (e.g., a T cell), wherein the circRNA is in a delivery vehicle, and a targeting moiety that binds to a T cell is conjugated to the delivery vehicle (e.g, a lipid nanoparticle).
Absstract of: US20260256940A1
0000 The current invention focuses on ways to deliver various payloads including nucleic acids molecules (such as oligonucleotides), polypeptides (such as proteins), drugs or a combination thereof. As such, the invention relates to, inter alia, a mitochondrion comprising one or more payload(s) attached to the outer membrane of the mitochondrion, wherein the payload(s) is indirectly or directly electrostatically attached to the outer membrane of the mitochondrion. The invention further involves combining mitochondria comprising one or more payload(s) attached to the outer membrane of the mitochondrion with a protective layer that envelopes/encapsules and/or coats the mitochondrion and payload to provide a further delivery platform. This methodology is particularly effective for increasing the uptake and efficiency of the one or more payload(s) for therapeutic purposes.
Nº publicación: US20260257986A1 03/09/2026
Applicant:
XIAMEN SINOPEG BIOTECH CO LTD [CN]
XIAMEN SINOPEG BIOTECH CO., LTD.
Absstract of: US20260257986A1
0000 The present invention introduces a novel amino acid-based cationic lipid, represented by the general formula (1), with symbols as defined herein. This lipid is pharmaceutically acceptable, biodegradable, or highly biocompatible, and offers low toxicity, low immunogenicity, and high compatibility. The amino acid or its derivatives used as starting materials are easily accessible, either naturally or through simple synthesis, making the process straightforward, safe, and cost-effective. The lipid structure may include degradable groups between the amino acid residue and lipophilic tail chains. The presence of degradable groups allows lipid nanoparticles (LNPs) to degrade within endosomes, addressing issues of LNP accumulation and endosomal acidification caused by non-degradable lipids in prior art. This facilitates the effective endosomal escape of drug molecules, such as nucleic acids, ensuring their proper cellular function after delivery.
0000
BOPI
Electronic site
